---
figid: PMC8386020__fphar-12-668567-g004
figtitle: Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers
organisms:
- Nicotiana tabacum
- Lareunionomyces loeiensis
- Curcuma longa
- Citrus macrophylla
- Azadirachta indica
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Canis lupus familiaris
- Avian myelocytomatosis virus
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Canis lupus familiaris
- Drosophila melanogaster
pmcid: PMC8386020
filename: fphar-12-668567-g004.jpg
figlink: /pmc/articles/PMC8386020/figure/F4/
number: F4
caption: 'EGFR signaling pathway: This schematic indicates the essential components
  of the RAS/RAF/MEK/ERK and PI3K/Akt/mTOR signaling pathways and their efficacy on
  the cascade of metastasis. EGFR, an activated receptor tyrosine kinase, triggers
  both cascades that result in the stimulation of Akt, mTOR-1/-2, and ERK as the downstream
  effectors. Some drug agents target these signaling pathways, including panitumumab,
  vemurafenib, dabrafenib, cetuximab, trastuzumab, and gefitinib, sorafenib, selumetinib,
  lapatinib, temsirolimus, erlotinib, perifosine, trametinib, everolimus. Curumin
  is able to inhibit EGFR signaling.'
papertitle: Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers.
reftext: Amirhossein Davoodvandi, et al. Front Pharmacol. 2021;12:668567.
year: '2021'
doi: 10.3389/fphar.2021.668567
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.
keywords: gastrointestinal cancer (GI cancer) | curcumin | therapy | metastasis |
  gastric cancer
automl_pathway: 0.8956864
figid_alias: PMC8386020__F4
figtype: Figure
redirect_from: /figures/PMC8386020__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8386020__fphar-12-668567-g004.html
  '@type': Dataset
  description: 'EGFR signaling pathway: This schematic indicates the essential components
    of the RAS/RAF/MEK/ERK and PI3K/Akt/mTOR signaling pathways and their efficacy
    on the cascade of metastasis. EGFR, an activated receptor tyrosine kinase, triggers
    both cascades that result in the stimulation of Akt, mTOR-1/-2, and ERK as the
    downstream effectors. Some drug agents target these signaling pathways, including
    panitumumab, vemurafenib, dabrafenib, cetuximab, trastuzumab, and gefitinib, sorafenib,
    selumetinib, lapatinib, temsirolimus, erlotinib, perifosine, trametinib, everolimus.
    Curumin is able to inhibit EGFR signaling.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - NR1H2
  - VEPH1
  - MYLK
  - MYLK2
  - MYLK3
  - INF2
  - AKT1
  - AKT2
  - AKT3
  - RHEB
  - RHEBP1
  - PTK2
  - EGFR
  - KDR
  - FLT1
  - FLT4
  - LAP
  - ACP2
  - TGFB1
  - PICALM
  - LAP3
  - CENPJ
  - PDON2
  - ARHGEF2
  - SLC2A4RG
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RAF1
  - Creb1
  - Mylk
  - Mylk3
  - Inf2
  - Inf2q
  - Akt1
  - Rheb
  - Ptk2
  - Egfr
  - Acp2
  - Cebpb
  - elap
  - Acp3
  - Lap3
  - Cenpj
  - Arhgef2
  - Sergef
  - Mdk
  - Raf1
  - Mylk2
  - Ccne1
  - ca
  - CrebB
  - CrebA
  - dome
  - Diedel
  - melt
  - Strn-Mlck
  - form3
  - Akt
  - Fak
  - Pvr
  - lap
  - Lap-A
  - PDZ-GEF
  - garz
  - RhoGEF64C
  - pbl
  - Dsor1
  - Mtk
  - CycE
  - cyc
---
